Coronavirus Disease 2019 Messenger RNA Vaccine Dose 3 Recipient Characteristics According to Severe Acute Respiratory Syndrome Coronavirus 2 Infection Status and Timing
| Characteristic . | Total Participants, No. (%) . | Vaccination-Only (ie, Never Infected), No. (%) . | Previous SARS-CoV-2 Infection, No. (%) . | SARS-CoV-2 Breakthrough Infection, No. (%) . | P Value . |
|---|---|---|---|---|---|
| All participants (row %) | 388 | 224 (0.6) | 123 (0.3) | 41 (0.1) | |
| Cohort location | |||||
| Tucson, Arizona | 113 (29.1) | 74 (33.0) | 22 (17.9) | 17 (41.5) | <.001* |
| Phoenix and other areas in Arizona | 82 (21.1) | 51 (22.8) | 27 (22.0) | 4 (9.8) | |
| Miami, Florida | 1 (0.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | |
| Duluth, Minnesota | 154 (39.7) | 97 (43.3) | 47 (38.2) | 10 (24.4) | |
| Portland, Oregon | 12 (3.1) | 0 (0.0) | 7 (5.7) | 5 (12.2) | |
| Temple, Texas | 4 (1.0) | 0 (0.0) | 3 (2.4) | 1 (2.4) | |
| Salt Lake City, Utah | 22 (5.7) | 2 (0.9) | 16 (13.0) | 4 (9.8) | |
| Sex | |||||
| Female | 267 (68.8) | 147 (65.6) | 92 (74.8) | 28 (68.3) | 0.210 |
| Male | 121 (31.2) | 77 (34.4) | 31 (25.2) | 13 (31.7) | |
| Age, y | |||||
| 18–39 | 224 (57.7) | 48 (21.4) | 47 (38.2) | 12 (29.3) | .002* |
| 40–64 | 123 (31.7) | 164 (73.2) | 70 (56.9) | 23 (56.1) | |
| ≥65 | 41 (10.6) | 12 (5.4) | 6 (4.9) | 6 (14.6) | |
| Race and ethnicity | |||||
| Non-Hispanic, White | 336 (86.6) | 193 (86.2) | 105 (85.4) | 38 (92.7) | |
| Non-Hispanic, Black | 1 (0.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | .826 |
| Non-Hispanic, Asian | 5 (1.3) | 3 (1.3) | 2 (1.6) | 0 (0.0) | |
| Hispanic | 39 (10.1) | 23 (10.3) | 13 (10.6) | 3 (7.3) | |
| Other | 7 (1.8) | 5 (2.2) | 2 (1.6) | 0 (0.0) | |
| Occupationa | |||||
| Primary HCP | 123 (31.7) | 79 (35.3) | 34 (27.6) | 10 (24.4) | .252 |
| Nurses and other allied HCP | 170 (43.8) | 95 (42.4) | 59 (48.0) | 16 (39.0) | |
| First responders | 18 (4.6) | 7 (3.1) | 8 (6.5) | 3 (7.3) | |
| Essential and other frontline workers | 77 (19.8) | 43 (19.2) | 22 (17.9) | 12 (29.3) | |
| Body mass indexb | |||||
| Underweight/Normal weightc | 142 (36.6) | 82 (36.6) | 48 (39.0) | 12 (29.3) | .522 |
| Overweight (25–29.9 kg/m2) | 129 (33.2) | 80 (35.7) | 32 (26.0) | 17 (41.5) | |
| Obese | 111 (28.6) | 61 (27.2) | 40 (32.5) | 10 (24.4) | |
| Chronic conditiond | |||||
| None | 247 (63.7) | 150 (67.0) | 72 (58.5) | 25 (61.0) | .512 |
| 1 or more | 138 (35.6) | 74 (33.0) | 49 (39.8) | 15 (36.6) | |
| Daily medications | |||||
| 0 | 142 (36.6) | 82 (36.6) | 46 (37.4) | 14 (34.1) | .957 |
| 1 | 84 (21.6) | 51 (22.8) | 25 (20.3) | 8 (19.5) | |
| 2 or more | 158 (40.7) | 90 (40.2) | 50 (40.7) | 18 (43.9) | |
| Smoking | |||||
| Not current smoker | 319 (82.2) | 184 (82.1) | 96 (78.0) | 39 (95.1) | .702 |
| Smoke tobacco products | 66 (17.0) | 40 (17.9) | 25 (20.3) | 1 (2.4) | |
| Influenza vaccination history in past 5 y | |||||
| No vaccination history | 20 (5.2) | 11 (4.9) | 8 (6.5) | 1 (2.4) | .294 |
| 1–3 y of vaccination | 19 (4.9) | 7 (3.1) | 9 (7.3) | 3 (7.3) | |
| ≥4 y of vaccination | 346 (89.2) | 206 (92.0) | 104 (84.6) | 36 (87.8) | |
| SARS-CoV-2 clinical presentatione | |||||
| CLI symptoms | 31 (81.6) | 19 (90.5) | .369 | ||
| Non-CLI associated symptomsf | 2 (5.3) | 0 (0.0) | |||
| Asymptomatic | 5 (13.2) | 2 (9.5) | |||
| SARS-CoV-2 detection duration, wk | |||||
| 1 | 8 (21.1) | 10 (47.6) | .034* | ||
| ≥2 | 30 (78.9) | 11 (52.4) | |||
| Febrile COVID-19 | |||||
| No | 15 (39.5) | 10 (47.6) | .442 | ||
| Yes | 23 (60.5) | 10 (47.6) | |||
| Medically attended COVID-19 | |||||
| No medical visit | 25 (65.8) | 17 (81.0) | .120 | ||
| 1 or more medical visits | 13 (34.2) | 3 (14.3) | |||
| COVID-19 vaccine products (all 3 doses) | |||||
| BNT162b2 | 340 (87.6) | 202 (90.2) | 106 (86.2) | 32 (78.0) | .222 |
| mRNA-1273 | 40 (10.3) | 19 (8.5) | 14 (11.4) | 7 (17.1) | |
| Combination | 8 (2.1) | 3 (1.3) | 3 (2.4) | 2 (4.9) |
| Characteristic . | Total Participants, No. (%) . | Vaccination-Only (ie, Never Infected), No. (%) . | Previous SARS-CoV-2 Infection, No. (%) . | SARS-CoV-2 Breakthrough Infection, No. (%) . | P Value . |
|---|---|---|---|---|---|
| All participants (row %) | 388 | 224 (0.6) | 123 (0.3) | 41 (0.1) | |
| Cohort location | |||||
| Tucson, Arizona | 113 (29.1) | 74 (33.0) | 22 (17.9) | 17 (41.5) | <.001* |
| Phoenix and other areas in Arizona | 82 (21.1) | 51 (22.8) | 27 (22.0) | 4 (9.8) | |
| Miami, Florida | 1 (0.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | |
| Duluth, Minnesota | 154 (39.7) | 97 (43.3) | 47 (38.2) | 10 (24.4) | |
| Portland, Oregon | 12 (3.1) | 0 (0.0) | 7 (5.7) | 5 (12.2) | |
| Temple, Texas | 4 (1.0) | 0 (0.0) | 3 (2.4) | 1 (2.4) | |
| Salt Lake City, Utah | 22 (5.7) | 2 (0.9) | 16 (13.0) | 4 (9.8) | |
| Sex | |||||
| Female | 267 (68.8) | 147 (65.6) | 92 (74.8) | 28 (68.3) | 0.210 |
| Male | 121 (31.2) | 77 (34.4) | 31 (25.2) | 13 (31.7) | |
| Age, y | |||||
| 18–39 | 224 (57.7) | 48 (21.4) | 47 (38.2) | 12 (29.3) | .002* |
| 40–64 | 123 (31.7) | 164 (73.2) | 70 (56.9) | 23 (56.1) | |
| ≥65 | 41 (10.6) | 12 (5.4) | 6 (4.9) | 6 (14.6) | |
| Race and ethnicity | |||||
| Non-Hispanic, White | 336 (86.6) | 193 (86.2) | 105 (85.4) | 38 (92.7) | |
| Non-Hispanic, Black | 1 (0.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | .826 |
| Non-Hispanic, Asian | 5 (1.3) | 3 (1.3) | 2 (1.6) | 0 (0.0) | |
| Hispanic | 39 (10.1) | 23 (10.3) | 13 (10.6) | 3 (7.3) | |
| Other | 7 (1.8) | 5 (2.2) | 2 (1.6) | 0 (0.0) | |
| Occupationa | |||||
| Primary HCP | 123 (31.7) | 79 (35.3) | 34 (27.6) | 10 (24.4) | .252 |
| Nurses and other allied HCP | 170 (43.8) | 95 (42.4) | 59 (48.0) | 16 (39.0) | |
| First responders | 18 (4.6) | 7 (3.1) | 8 (6.5) | 3 (7.3) | |
| Essential and other frontline workers | 77 (19.8) | 43 (19.2) | 22 (17.9) | 12 (29.3) | |
| Body mass indexb | |||||
| Underweight/Normal weightc | 142 (36.6) | 82 (36.6) | 48 (39.0) | 12 (29.3) | .522 |
| Overweight (25–29.9 kg/m2) | 129 (33.2) | 80 (35.7) | 32 (26.0) | 17 (41.5) | |
| Obese | 111 (28.6) | 61 (27.2) | 40 (32.5) | 10 (24.4) | |
| Chronic conditiond | |||||
| None | 247 (63.7) | 150 (67.0) | 72 (58.5) | 25 (61.0) | .512 |
| 1 or more | 138 (35.6) | 74 (33.0) | 49 (39.8) | 15 (36.6) | |
| Daily medications | |||||
| 0 | 142 (36.6) | 82 (36.6) | 46 (37.4) | 14 (34.1) | .957 |
| 1 | 84 (21.6) | 51 (22.8) | 25 (20.3) | 8 (19.5) | |
| 2 or more | 158 (40.7) | 90 (40.2) | 50 (40.7) | 18 (43.9) | |
| Smoking | |||||
| Not current smoker | 319 (82.2) | 184 (82.1) | 96 (78.0) | 39 (95.1) | .702 |
| Smoke tobacco products | 66 (17.0) | 40 (17.9) | 25 (20.3) | 1 (2.4) | |
| Influenza vaccination history in past 5 y | |||||
| No vaccination history | 20 (5.2) | 11 (4.9) | 8 (6.5) | 1 (2.4) | .294 |
| 1–3 y of vaccination | 19 (4.9) | 7 (3.1) | 9 (7.3) | 3 (7.3) | |
| ≥4 y of vaccination | 346 (89.2) | 206 (92.0) | 104 (84.6) | 36 (87.8) | |
| SARS-CoV-2 clinical presentatione | |||||
| CLI symptoms | 31 (81.6) | 19 (90.5) | .369 | ||
| Non-CLI associated symptomsf | 2 (5.3) | 0 (0.0) | |||
| Asymptomatic | 5 (13.2) | 2 (9.5) | |||
| SARS-CoV-2 detection duration, wk | |||||
| 1 | 8 (21.1) | 10 (47.6) | .034* | ||
| ≥2 | 30 (78.9) | 11 (52.4) | |||
| Febrile COVID-19 | |||||
| No | 15 (39.5) | 10 (47.6) | .442 | ||
| Yes | 23 (60.5) | 10 (47.6) | |||
| Medically attended COVID-19 | |||||
| No medical visit | 25 (65.8) | 17 (81.0) | .120 | ||
| 1 or more medical visits | 13 (34.2) | 3 (14.3) | |||
| COVID-19 vaccine products (all 3 doses) | |||||
| BNT162b2 | 340 (87.6) | 202 (90.2) | 106 (86.2) | 32 (78.0) | .222 |
| mRNA-1273 | 40 (10.3) | 19 (8.5) | 14 (11.4) | 7 (17.1) | |
| Combination | 8 (2.1) | 3 (1.3) | 3 (2.4) | 2 (4.9) |
Abbreviations: CLI, COVID-19-like illness; COVID-19, coronavirus disease 2019; HCP, healthcare provider; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
*Statistically significant.
Primary HCPs include medical doctor, doctors of osteopathic medicine, nurse practitioners, and physician assistants.
Body mass index, kg/m2: underweight, ≤18.4; normal, 18.5–24.9; overweight, 25–29.9; obese, BMI ≥30.
Only 1 participant was underweight by 0.6 and therefore combined with normal weight.
Chronic conditions include asthma, autoimmune disease, chronic lung disease, cancer, diabetes, heart disease, hypertension, immunosuppression, kidney disease, liver disease, and neurologic or neuromuscular disease.
Includes only 59 infections that occurred during the active surveillance study period. Those with a self-reported infection prior to enrollment are excluded from this section as infection characteristics are unknown.
Non-CLI symptoms included headache, nausea, and fatigue.
Coronavirus Disease 2019 Messenger RNA Vaccine Dose 3 Recipient Characteristics According to Severe Acute Respiratory Syndrome Coronavirus 2 Infection Status and Timing
| Characteristic . | Total Participants, No. (%) . | Vaccination-Only (ie, Never Infected), No. (%) . | Previous SARS-CoV-2 Infection, No. (%) . | SARS-CoV-2 Breakthrough Infection, No. (%) . | P Value . |
|---|---|---|---|---|---|
| All participants (row %) | 388 | 224 (0.6) | 123 (0.3) | 41 (0.1) | |
| Cohort location | |||||
| Tucson, Arizona | 113 (29.1) | 74 (33.0) | 22 (17.9) | 17 (41.5) | <.001* |
| Phoenix and other areas in Arizona | 82 (21.1) | 51 (22.8) | 27 (22.0) | 4 (9.8) | |
| Miami, Florida | 1 (0.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | |
| Duluth, Minnesota | 154 (39.7) | 97 (43.3) | 47 (38.2) | 10 (24.4) | |
| Portland, Oregon | 12 (3.1) | 0 (0.0) | 7 (5.7) | 5 (12.2) | |
| Temple, Texas | 4 (1.0) | 0 (0.0) | 3 (2.4) | 1 (2.4) | |
| Salt Lake City, Utah | 22 (5.7) | 2 (0.9) | 16 (13.0) | 4 (9.8) | |
| Sex | |||||
| Female | 267 (68.8) | 147 (65.6) | 92 (74.8) | 28 (68.3) | 0.210 |
| Male | 121 (31.2) | 77 (34.4) | 31 (25.2) | 13 (31.7) | |
| Age, y | |||||
| 18–39 | 224 (57.7) | 48 (21.4) | 47 (38.2) | 12 (29.3) | .002* |
| 40–64 | 123 (31.7) | 164 (73.2) | 70 (56.9) | 23 (56.1) | |
| ≥65 | 41 (10.6) | 12 (5.4) | 6 (4.9) | 6 (14.6) | |
| Race and ethnicity | |||||
| Non-Hispanic, White | 336 (86.6) | 193 (86.2) | 105 (85.4) | 38 (92.7) | |
| Non-Hispanic, Black | 1 (0.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | .826 |
| Non-Hispanic, Asian | 5 (1.3) | 3 (1.3) | 2 (1.6) | 0 (0.0) | |
| Hispanic | 39 (10.1) | 23 (10.3) | 13 (10.6) | 3 (7.3) | |
| Other | 7 (1.8) | 5 (2.2) | 2 (1.6) | 0 (0.0) | |
| Occupationa | |||||
| Primary HCP | 123 (31.7) | 79 (35.3) | 34 (27.6) | 10 (24.4) | .252 |
| Nurses and other allied HCP | 170 (43.8) | 95 (42.4) | 59 (48.0) | 16 (39.0) | |
| First responders | 18 (4.6) | 7 (3.1) | 8 (6.5) | 3 (7.3) | |
| Essential and other frontline workers | 77 (19.8) | 43 (19.2) | 22 (17.9) | 12 (29.3) | |
| Body mass indexb | |||||
| Underweight/Normal weightc | 142 (36.6) | 82 (36.6) | 48 (39.0) | 12 (29.3) | .522 |
| Overweight (25–29.9 kg/m2) | 129 (33.2) | 80 (35.7) | 32 (26.0) | 17 (41.5) | |
| Obese | 111 (28.6) | 61 (27.2) | 40 (32.5) | 10 (24.4) | |
| Chronic conditiond | |||||
| None | 247 (63.7) | 150 (67.0) | 72 (58.5) | 25 (61.0) | .512 |
| 1 or more | 138 (35.6) | 74 (33.0) | 49 (39.8) | 15 (36.6) | |
| Daily medications | |||||
| 0 | 142 (36.6) | 82 (36.6) | 46 (37.4) | 14 (34.1) | .957 |
| 1 | 84 (21.6) | 51 (22.8) | 25 (20.3) | 8 (19.5) | |
| 2 or more | 158 (40.7) | 90 (40.2) | 50 (40.7) | 18 (43.9) | |
| Smoking | |||||
| Not current smoker | 319 (82.2) | 184 (82.1) | 96 (78.0) | 39 (95.1) | .702 |
| Smoke tobacco products | 66 (17.0) | 40 (17.9) | 25 (20.3) | 1 (2.4) | |
| Influenza vaccination history in past 5 y | |||||
| No vaccination history | 20 (5.2) | 11 (4.9) | 8 (6.5) | 1 (2.4) | .294 |
| 1–3 y of vaccination | 19 (4.9) | 7 (3.1) | 9 (7.3) | 3 (7.3) | |
| ≥4 y of vaccination | 346 (89.2) | 206 (92.0) | 104 (84.6) | 36 (87.8) | |
| SARS-CoV-2 clinical presentatione | |||||
| CLI symptoms | 31 (81.6) | 19 (90.5) | .369 | ||
| Non-CLI associated symptomsf | 2 (5.3) | 0 (0.0) | |||
| Asymptomatic | 5 (13.2) | 2 (9.5) | |||
| SARS-CoV-2 detection duration, wk | |||||
| 1 | 8 (21.1) | 10 (47.6) | .034* | ||
| ≥2 | 30 (78.9) | 11 (52.4) | |||
| Febrile COVID-19 | |||||
| No | 15 (39.5) | 10 (47.6) | .442 | ||
| Yes | 23 (60.5) | 10 (47.6) | |||
| Medically attended COVID-19 | |||||
| No medical visit | 25 (65.8) | 17 (81.0) | .120 | ||
| 1 or more medical visits | 13 (34.2) | 3 (14.3) | |||
| COVID-19 vaccine products (all 3 doses) | |||||
| BNT162b2 | 340 (87.6) | 202 (90.2) | 106 (86.2) | 32 (78.0) | .222 |
| mRNA-1273 | 40 (10.3) | 19 (8.5) | 14 (11.4) | 7 (17.1) | |
| Combination | 8 (2.1) | 3 (1.3) | 3 (2.4) | 2 (4.9) |
| Characteristic . | Total Participants, No. (%) . | Vaccination-Only (ie, Never Infected), No. (%) . | Previous SARS-CoV-2 Infection, No. (%) . | SARS-CoV-2 Breakthrough Infection, No. (%) . | P Value . |
|---|---|---|---|---|---|
| All participants (row %) | 388 | 224 (0.6) | 123 (0.3) | 41 (0.1) | |
| Cohort location | |||||
| Tucson, Arizona | 113 (29.1) | 74 (33.0) | 22 (17.9) | 17 (41.5) | <.001* |
| Phoenix and other areas in Arizona | 82 (21.1) | 51 (22.8) | 27 (22.0) | 4 (9.8) | |
| Miami, Florida | 1 (0.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | |
| Duluth, Minnesota | 154 (39.7) | 97 (43.3) | 47 (38.2) | 10 (24.4) | |
| Portland, Oregon | 12 (3.1) | 0 (0.0) | 7 (5.7) | 5 (12.2) | |
| Temple, Texas | 4 (1.0) | 0 (0.0) | 3 (2.4) | 1 (2.4) | |
| Salt Lake City, Utah | 22 (5.7) | 2 (0.9) | 16 (13.0) | 4 (9.8) | |
| Sex | |||||
| Female | 267 (68.8) | 147 (65.6) | 92 (74.8) | 28 (68.3) | 0.210 |
| Male | 121 (31.2) | 77 (34.4) | 31 (25.2) | 13 (31.7) | |
| Age, y | |||||
| 18–39 | 224 (57.7) | 48 (21.4) | 47 (38.2) | 12 (29.3) | .002* |
| 40–64 | 123 (31.7) | 164 (73.2) | 70 (56.9) | 23 (56.1) | |
| ≥65 | 41 (10.6) | 12 (5.4) | 6 (4.9) | 6 (14.6) | |
| Race and ethnicity | |||||
| Non-Hispanic, White | 336 (86.6) | 193 (86.2) | 105 (85.4) | 38 (92.7) | |
| Non-Hispanic, Black | 1 (0.3) | 0 (0.0) | 1 (0.8) | 0 (0.0) | .826 |
| Non-Hispanic, Asian | 5 (1.3) | 3 (1.3) | 2 (1.6) | 0 (0.0) | |
| Hispanic | 39 (10.1) | 23 (10.3) | 13 (10.6) | 3 (7.3) | |
| Other | 7 (1.8) | 5 (2.2) | 2 (1.6) | 0 (0.0) | |
| Occupationa | |||||
| Primary HCP | 123 (31.7) | 79 (35.3) | 34 (27.6) | 10 (24.4) | .252 |
| Nurses and other allied HCP | 170 (43.8) | 95 (42.4) | 59 (48.0) | 16 (39.0) | |
| First responders | 18 (4.6) | 7 (3.1) | 8 (6.5) | 3 (7.3) | |
| Essential and other frontline workers | 77 (19.8) | 43 (19.2) | 22 (17.9) | 12 (29.3) | |
| Body mass indexb | |||||
| Underweight/Normal weightc | 142 (36.6) | 82 (36.6) | 48 (39.0) | 12 (29.3) | .522 |
| Overweight (25–29.9 kg/m2) | 129 (33.2) | 80 (35.7) | 32 (26.0) | 17 (41.5) | |
| Obese | 111 (28.6) | 61 (27.2) | 40 (32.5) | 10 (24.4) | |
| Chronic conditiond | |||||
| None | 247 (63.7) | 150 (67.0) | 72 (58.5) | 25 (61.0) | .512 |
| 1 or more | 138 (35.6) | 74 (33.0) | 49 (39.8) | 15 (36.6) | |
| Daily medications | |||||
| 0 | 142 (36.6) | 82 (36.6) | 46 (37.4) | 14 (34.1) | .957 |
| 1 | 84 (21.6) | 51 (22.8) | 25 (20.3) | 8 (19.5) | |
| 2 or more | 158 (40.7) | 90 (40.2) | 50 (40.7) | 18 (43.9) | |
| Smoking | |||||
| Not current smoker | 319 (82.2) | 184 (82.1) | 96 (78.0) | 39 (95.1) | .702 |
| Smoke tobacco products | 66 (17.0) | 40 (17.9) | 25 (20.3) | 1 (2.4) | |
| Influenza vaccination history in past 5 y | |||||
| No vaccination history | 20 (5.2) | 11 (4.9) | 8 (6.5) | 1 (2.4) | .294 |
| 1–3 y of vaccination | 19 (4.9) | 7 (3.1) | 9 (7.3) | 3 (7.3) | |
| ≥4 y of vaccination | 346 (89.2) | 206 (92.0) | 104 (84.6) | 36 (87.8) | |
| SARS-CoV-2 clinical presentatione | |||||
| CLI symptoms | 31 (81.6) | 19 (90.5) | .369 | ||
| Non-CLI associated symptomsf | 2 (5.3) | 0 (0.0) | |||
| Asymptomatic | 5 (13.2) | 2 (9.5) | |||
| SARS-CoV-2 detection duration, wk | |||||
| 1 | 8 (21.1) | 10 (47.6) | .034* | ||
| ≥2 | 30 (78.9) | 11 (52.4) | |||
| Febrile COVID-19 | |||||
| No | 15 (39.5) | 10 (47.6) | .442 | ||
| Yes | 23 (60.5) | 10 (47.6) | |||
| Medically attended COVID-19 | |||||
| No medical visit | 25 (65.8) | 17 (81.0) | .120 | ||
| 1 or more medical visits | 13 (34.2) | 3 (14.3) | |||
| COVID-19 vaccine products (all 3 doses) | |||||
| BNT162b2 | 340 (87.6) | 202 (90.2) | 106 (86.2) | 32 (78.0) | .222 |
| mRNA-1273 | 40 (10.3) | 19 (8.5) | 14 (11.4) | 7 (17.1) | |
| Combination | 8 (2.1) | 3 (1.3) | 3 (2.4) | 2 (4.9) |
Abbreviations: CLI, COVID-19-like illness; COVID-19, coronavirus disease 2019; HCP, healthcare provider; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
*Statistically significant.
Primary HCPs include medical doctor, doctors of osteopathic medicine, nurse practitioners, and physician assistants.
Body mass index, kg/m2: underweight, ≤18.4; normal, 18.5–24.9; overweight, 25–29.9; obese, BMI ≥30.
Only 1 participant was underweight by 0.6 and therefore combined with normal weight.
Chronic conditions include asthma, autoimmune disease, chronic lung disease, cancer, diabetes, heart disease, hypertension, immunosuppression, kidney disease, liver disease, and neurologic or neuromuscular disease.
Includes only 59 infections that occurred during the active surveillance study period. Those with a self-reported infection prior to enrollment are excluded from this section as infection characteristics are unknown.
Non-CLI symptoms included headache, nausea, and fatigue.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
